The Absolute Effect / Evidence index
Relapsed / Refractory · Randomized phase II; N=160 transplant-ineligible second-line LBCL. Zamtocabtagene autoleucel (zamto-cel) vs R-GemOx. Primary endpoint independently reviewed EFS. · Median EFS 6.21 vs 2.53 months
DALY 2-EU
Clinical question: Does zamtocabtagene autoleucel improve EFS over R-GemOx in transplant-ineligible second-line large B-cell lymphoma?
Median EFS 6.21 vs 2.53 months; HR 0.39 (95% CI 0.27–0.58; P<0.0001). · Registry:
Design, population and treatment
Randomized phase II; N=160 transplant-ineligible second-line LBCL. Zamtocabtagene autoleucel (zamto-cel) vs R-GemOx. Primary endpoint independently reviewed EFS.
Key efficacy outcome
Grade ≥3 TEAEs 83% vs 86%; two treatment-related deaths (3%) with CAR T vs one (1%) with R-GemOx; CRS/ICANS observed with CAR T.
Safety and absolute effect
Median EFS (months)
https://pubmed.ncbi.nlm.nih.gov/42933440/
Interpretation and limitations
Current-practice context · 14 November 2026: Primary publication/abstract and trial identifier checked. Guideline-level current-practice mapping was not established in this publication-led batch; no NCCN citation provenance is claimed. Where detailed QoL, follow-up or toxicity data were not present in the retrieved abstract, they are not inferred.